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Abstract
Purpose The purpose of this drug utilization study was to
describe the use of rivaroxaban in Germany during a time
period in which approval was limited to the prevention of
venous thromboembolism following hip or knee replacement.
Additionally, we explored the feasibility of reconstructing
inpatient drug use of rivaroxaban in a database where with a
few exceptions inpatient prescribing information is not
available.
Methods Source of data was one statutory health insurance
providing data on about seven million insurants throughout
Germany. Analyses were based on a cohort of rivaroxaban
users from launch (October 2008) to December 2009 and
encompassed potential indications for rivaroxaban use, treat-
ment duration, and co-prescribing of potentially interacting
drugs. Start of rivaroxaban treatment was defined by the date
of surgery.
Results During the study period, 425 rivaroxaban users were
identified contributing 440 treatment periods. For more than
82 % of these episodes labelled indications could be deter-
mined. Treatment durations exceeded recommendations in
95 % of the episodes following knee replacement whereas
rivaroxaban use after elective hip surgery was found to be
longer than recommended in 56 %. Prescribing of potentially
interacting medication was rare except for non-steroidal anti-
inflammatory drugs.
Conclusions Overall, no important off-label use of
rivaroxaban was identified. Based on several assumptions that
have to be considered in the interpretation of the results our
study describes a database approach to reconstruct inpatient
drug use for a drug started after a coded hospital procedure,
when treatment continues after hospital discharge and no
change in drug use is expected in the outpatient setting.
Keywords Rivaroxaban . Drug utilization . Inpatient drug
use . German Pharmacoepidemiological ResearchDatabase
Introduction
Major orthopaedic surgery is associated with a high risk of
venous thromboembolism (VTE), thus routine use of prophy-
laxis is recommended [1–3].
In Germany, post-surgical thromboprophylaxis has been
traditionally conducted with low molecular weight heparins
(LMWHs) or the indirect factor Xa inhibitor fondaparinux [1].
However, as these agents are administered subcutaneously,
which might affect patients’ compliance, new oral
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anticoagulants have been developed aiming at simplifying
thromboprophylaxis [4]. One of these new agents is the selec-
tive factor Xa inhibitor rivaroxaban (Xarelto®) which was
approved for the prevention of VTE in adult patients under-
going elective hip or knee replacement surgery in 2008 [5].
Subsequently, approval was gained for the prevention of
stroke and systemic embolism in adults with non-valvular
atrial fibrillation with one or more risk factors and for the
treatment of deep vein thrombosis (DVT) and pulmonary
embolism (PE), and prevention of recurrent DVT and PE in
2011 and 2012 [6]. The recommended daily dose of
rivaroxaban for the orthopaedic indications is 10 mg once
daily for 5 weeks in patients undergoing hip replacement
(HR) and for 14 days following knee replacement (KR) sur-
gery, respectively [5, 7].
Rivaroxaban is contraindicated in patients with hepatic
disease associated with coagulopathy and clinically relevant
bleeding risk. Caution is to be taken in patients with severe
renal impairment, and rivaroxaban use is not recommended in
patients with creatinine clearance <15 ml/min. Rivaroxaban is
contraindicated in pregnant or breast-feeding women and not
recommended in persons up to 18 years [5, 7]. In patients
receiving concomitant systemic treatment with strong inhibi-
tors of both cytochrome P450 (CYP) 3A4 and P-glycoprotein
(P-gp) use of rivaroxaban is not recommended. Additionally,
strong CYP3A4 inducers should be co-administered with
caution, and care is to be taken if patients are treated concom-
itantly with drugs affecting haemostasis [5, 7].
For new agents drug utilization studies (DUS) are increas-
ingly required in the context of risk management plans and the
evaluation of risk minimization activities e.g. exploring how
medicinal products are prescribed and used in routine clinical
practice and if the drugs of interest are applied within the
licensed indications [8]. For this type of studies, claims data-
bases or medical records databases are frequently used, since
they are usually representative and complete for large patient
populations and allow exploration of real-world utilization
patterns without influencing the physicians’ prescription be-
haviour as it may be the case in studies using primary data
collection. One drawback of these databases, however, is that
drug use information usually is limited to outpatient prescrip-
tions hampering determination of medication applied in hos-
pital [9].
The purpose of this study was to describe how rivaroxaban
was used in Germany during a time period in which approval
was limited to the orthopaedic indication. This encompassed
the distribution of rivaroxaban use by age, sex, potential
indications, duration of use, and compliance with contraindi-
cations and precautions. This DUS also offered the oppor-
tunity to explore the feasibility of reconstructing inpa-
tient drug use of rivaroxaban in a database where with a
few exceptions inpatient prescribing information is not
available.
Methods
This retrospective cohort study was based on data from one of
the four statutory health insurance providers (SHI) included in
the German Pharmacoepidemiological Research Database
(GePaRD). This database has been built by the Leibniz Insti-
tute for Prevention Research and Epidemiology–BIPS and
contains demographic characteristics for each person, infor-
mation on hospitalizations and outpatient physician visits as
well as outpatient prescription data. A detailed description of
GePaRD can be found in the online supplement.
The SHI providing data for this study represents a total
population of about seven million insurants from all over
Germany.
The study period was from October 2008 when
rivaroxaban was launched in Germany to December 2009.
Patients were included in the study cohort if they (i) received
an outpatient prescription of rivaroxaban and (ii) had been
continuously insured for at least 24 months preceding cohort
entry which was defined as the reconstructed start of
rivaroxaban treatment. For the licensed indications,
rivaroxaban was supposed to be initiated in hospital within 6
to 10 hours after elective surgery [5, 7] and to continue after
hospital discharge. An inpatient start of rivaroxaban treatment
was assumed, when an outpatient prescription was observed
after hospital discharge. Thus, cohort entry was defined as (i)
the in-hospital date of surgery if a respective procedure could
be identified via diagnostic and therapeutic procedures coded
according to the Operations and Procedures Coding System
(OPS), (ii) the date of hospital admission if another indication
than surgery could be determined in hospital or (iii) the date of
the first outpatient rivaroxaban prescription if no indication for
rivaroxaban use could be identified in the hospital data. The
duration of a rivaroxaban prescription was estimated by the
amount of dispensed tablets which in the orthopaedic indica-
tions equalled the number of defined daily doses (DDDs).
Allowing for a gap of maximum 14 days, subsequent pre-
scriptions were considered as one treatment episode. Cohort
exit was defined as the estimated end of the last rivaroxaban
treatment episode, the end of the study period, death of any
cause or the end of insurance, whatever happened first.
For each treatment episode, potential indications were de-
termined in a hierarchical approach comprising four groups:
(i) elective HR and KR as well as respective revisions which
were approved during the study period, (ii) non-labelled or-
thopaedic indications such as HR or KR following fracture as
well as other surgical interventions and (iii) non-labelled
cardiovascular indications including atrial fibrillation and the
treatment of DVT or PE. A fourth group comprised all epi-
sodes for which none of these indications could be identified.
To account for the hospital stay and a possible transfer to a
rehabilitation clinic, potential indications were assessed in the
90 days prior to the first outpatient rivaroxaban prescription of
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an episode. In two additional analyses, we extended the time
window to (i) 180 days before and (ii) 90 days following this
first prescription, respectively. Potential indicationswere iden-
tified from the in- and outpatient setting via surgical proce-
dures and diagnoses obtained from OPS and the German
modification of the International Classification of Diseases,
10th revision (ICD-10-GM) codes (codes are available on
request). To differentiate between elective interventions and
fracture surgery, the latter was assumed if the respective OPS
codes and diagnoses indicating fracture were found during the
same hospital stay. In this case, the episodes were allocated to
non-labelled orthopaedic and surgical indications instead of
elective KR or HR.
Presence of liver and renal impairment (ICD-10-GM codes
are available on request) was assessed in the 24 months pre-
ceding cohort entry and during rivaroxaban treatment. In an
additional analysis the assessment period encompassed the
180 days prior to cohort entry and the time of rivaroxaban
treatment.
Based on predefined pregnancy and birth markers [10],
women of childbearing age (11-50 years at cohort entry) were
screened for pregnancy within 270 days prior to cohort entry
up to 270 days after the estimated end of the last rivaroxaban
treatment episode.
Co-medications were examined during outpatient
rivaroxaban treatment and included those listed in the German
Summary of Products Characteristics (SPC) [7] and were also
extended to other CYP3A4 inhibitors and inducers [11].
Analyses were performed using SAS software (version 9.2;
SAS Institute Inc., Cary, NC).
Results
During the study period, 425 users of rivaroxaban met the
inclusion criteria; of those, 201 were male and 224 female.
Mean age at cohort entry was 63.8 years and almost two-third
of them were between 60 and 79 years (Table 1). No
rivaroxaban prescription was identified in patients younger
than 18 years, and none of the women of childbearing age (N=
31) was found to be pregnant during rivaroxaban treatment.
Overall, 440 continuous episodes in 425 individuals were
identified with men being more likely to have multiple treat-
ment periods than women (5.5 vs. 1.8 %). Outpatient
rivaroxaban treatment was mostly initiated by general practi-
tioners (57.0 %), followed by orthopaedic surgeons (19.3 %)
and surgeons (8.6 %).
Most of the rivaroxaban treatment episodes could be re-
ferred to HR (44.1 %) or KR (33.9 %). For 20 (4.5 %)
episodes, revision of HR or KR was identified as indication
(Table 2). Overall, 363 (82.5%) episodes were found to be on-
label. Non-labelled orthopaedic and surgical use including
five episodes of HR or KR following fracture was determined
in 8.9 %, whereas 2.5 % of treatment periods referred to non-
labelled cardiovascular indications. For about 6 % of the
episodes, no indication could be determined. Overall, men
were more likely to receive rivaroxaban on-label than women
(86.8 vs. 78.5 %).
Extending the time window for the assessment of indica-
tions to 180 days before and 90 days following the first
rivaroxaban prescription revealed 11 additional on-label epi-
sodes decreasing the number of treatment periods without







Age at cohort entry
Mean (std) 64.2 (10.4) 63.4 (11.6) 63.8 (11.0)
<18 years 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
18–39 years 2 (1.0 %) 11 (4.9 %) 13 (3.1 %)
40–59 years 65 (32.3 %) 55 (24.6 %) 120 (28.2 %)
60–79 years 123 (61.2 %) 152 (67.9 %) 275 (64.7 %)
≥80 years 11 (5.5 %) 6 (2.7 %) 17 (4.0 %)
Multiple treatment
episodes
11 (5.5 %) 4 (1.8 %) 15 (3.5 %)
Table 2 On-label and non-la-
belled use for rivaroxaban treat-







On-label use 184 (86.8 %) 179 (78.5 %) 363 (82.5 %)
Elective HR 107 (50.5 %) 87 (38.2 %) 194 (44.1 %)
Elective KR 68 (32.1 %) 81 (35.5 %) 149 (33.9 %)
Revision of HR 7 (3.3 %) 5 (2.2 %) 12 (2.7 %)
Revision of KR 2 (0.9 %) 6 (2.6 %) 8 (1.8 %)
Use in non-labelled orthopaedic and surgical indications 13 (6.1 %) 26 (11.4 %) 39 (8.9 %)
Use in non-labelled cardiovascular indications 3 (1.4 %) 8 (3.5 %) 11 (2.5 %)
Indication for use unknown 12 (5.7 %) 15 (6.6 %) 27 (6.1 %)
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indication to 17 (3.9 %) and increasing the proportion of on-
label episodes to 85.0 %.
HR was the most frequent indication across almost all age
groups with the exception of patients aged 80 years or older
where KR was most prominent (Fig. 1). The proportion of on-
label use was highest in patients aged 60 to 79 and lowest in
those being 18 to 39 years old. This latter group, however,
comprised only 13 patients.
Median treatment duration was 36 days after KR and
38 days following HR with the Kaplan-Meier curves showing
similar shapes for both indications (see Fig. 2 in the online
supplement). As displayed in Table 3, rivaroxaban treatment
after elective KR was longer than the 14 days stated in the
SPC in more than 95 %. These findings were less pronounced
in HR where 56.2 % of the treatment duration exceeded the
recommended 5 weeks. Treatment was shorter than recom-
mended in 3.2 % of the episodes following KR and in 42.7 %
after HR.
Regarding the 24 months preceding cohort entry and the
time during rivaroxaban treatment, liver impairment was
found in 65 (15.3 %) patients, whereas the definition of renal
impairment was met by 24 (5.7 %). Of those patients for
whom a stage of chronic renal failure could be deduced from
the ICD codes (N=16), none was found with a creatinine
clearance <30 ml/min. The numbers of patients diagnosed
with liver or renal impairment decreased to 45 (10.6 %) and
18 (4.2 %), respectively considering the shorter time window.
Frequencies of potentially interacting drugs prescribed dur-
ing rivaroxaban treatment are given in Table 4. CYP3A4
inhibiting medications mainly comprised the weak inhibitor
ciprofloxacin which was prescribed to 9 patients whereas
prescribing of CYP3A4 inducers and P-gp inhibitors was rare.
Nearly half of the patients (48.2 %) received drugs affecting
haemostasis, mainly non-steroidal anti-inflammatory drugs
(NSAIDs) with ibuprofen and diclofenac being used most
frequently. Low-dose acetylsalicylic acid was the only platelet
aggregation inhibitor prescribed. During 15 (3.4 %)
rivaroxaban treatment periods, prescriptions of LMWH or
fondaparinux were identified, 5 of these concomitantly on
the date of the first rivaroxaban prescription. No other antico-
agulants such as Vitamin K antagonists (VKA) were pre-
scribed to patients receiving rivaroxaban.
Discussion
In this study reflecting real life practice in Germany, we
examined rivaroxaban use in a cohort of more than 400
patients. We also explored an approach to investigate drug












18-39 years 40-59 years 60-79 years >=80 years All
Elective HR Elective KR
Revision of HR Revision of KR
Use in non-labelled orthopaedic and
surgical indications
Use in non-labelled cardiovascular indications
Indication for use unkown
Fig. 1 Distribution of potential
indications stratified by age group
Table 3 Duration of rivaroxaban treatment for labelled indications
Duration of treatment episode No. of episodes
Elective KR, revision of KR N=157
<11 days 3 (1.9 %)
11–<14 days 2 (1.3 %)
14 days 2 (1.3 %)
>14–21 days 35 (22.3 %)
>21–35 days 32 (20.4 %)
>35 days 83 (52.9 %)
Elective HR, revision of HR N=206
<4 weeks 73 (35.4 %)
4–<5 weeks 15 (7.3 %)
5 weeks 2 (1.0 %)
>5–6 weeks 58 (28.2 %)
>6 weeks 58 (28.2 %)
Recommended treatment durations for rivaroxaban according to the SPC
are 14 days in patients undergoing KR and 5 weeks in those undergoing
HR. The German S3-Gu ide l ine gene ra l l y recommends
thromboprophylaxis for 11–14 days after KR and for 4–5 weeks after
HR, respectively
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in-hospital prescribing information with a few exceptions is
not available in the database providing data for this study.
This approach was based on several considerations: (i)
during the study period, approval was limited to HR and KR
thus a related in-hospital surgical procedure providing an
exact date was likely; (ii) though thromboprophylaxis after
KR or HR is recommended for only 14 days or 5 weeks,
respectively, the tendency towards shorter stays in hospital
after surgery [12] probably leads to a continuation of treatment
in the outpatient setting where rivaroxaban use can be identi-
fied and its use extrapolated to the inpatient setting; (iii) as in
Germanywith hospital discharge only a very limited supply of
medication e.g. to cover the weekend is given to the patient
[13] an outpatient prescription within a few days after dis-
charge could be expected; (iv) a change of treatment from
subcutaneous injections of LMWH or fondaparinux in hospi-
tal to rivaroxaban after dischargewas unlikely since during the
time of the study rivaroxaban increased the costs for
thromboprophylaxis compared to e.g. the LMWH enoxaparin
or the indirect factor Xa inhibitor fondaparinux in the outpa-
tient setting [14].
During the study period, for more than 91 % of the patients
receiving an outpatient prescription of rivaroxaban, a preced-
ing orthopaedic or surgical procedure could be identified
qualifying for an in-hospital start of treatment. Overall, more
than 82% of the rivaroxaban treatment episodes were found to
be on-label. Half of the remaining treatment periods were
referred to other orthopaedic and surgical interventions in-
cluding a small proportion of fracture surgery. Less than 3 %
of the episodes were allocated to the cardiovascular indica-
tions approved in 2011 and 2012 and for 6 % no indication
could be determined by our algorithm examining the 90 days
preceding the first rivaroxaban prescription. However, extend-
ing the time interval to 180 days before and to 90 days
following the first rivaroxaban prescription decreased the
number of treatment episodes with no plausible indication to
less than 4 %. Especially, including the 90 days following this
first prescription yielded additional on-label indications. This
might imply that rivaroxaban in these instances was pre-
scribed prior to surgery and might partly be explained by
office-based physicians with hospital affiliations conducting
inpatient surgeries while prescriptions are organized by the
medical practice and given to the patient before the interven-
tion. The relatively high proportion of outpatient rivaroxaban
treatment initiated by orthopaedic and other surgeons supports
this assumption. Among those episodes where a potential
indication for rivaroxaban use could be determined, 88 %
were found to be on-label.
Overall, the recommendations on the duration of
rivaroxaban use were not followed in most patients. In nearly
three quarters of episodes, treatment exceeded the advised
durations. The prolonged use which was mainly observed
following KRmight have been influenced by other guidelines
such as the American College of Chest Physicians (ACCP)
Evidence-Based Clinical Practice Guidelines published in
2008 (8th edition) suggesting that thromboprophylaxis for
these patients be extended up to 35 days after surgery [2].
Additionally, physicians might have chosen a prolonged treat-
ment based on a patient’s clinical condition affecting post-
surgery mobilization.
On the other hand, treatment was shorter than recommend-
ed in about one quarter of episodes putting patients at potential
risk of thromboembolic events. These findings mainly applied
to treatment following HR. Results of a similar magnitude
were also reported from the multinational Global Orthopaedic
Registry (GLORY) revealing that of those who received rec-
ommended forms of VTE prophylaxis after HR or KR the
duration was shorter than recommended in approximately one
quarter of the patients [15].
No patients were found to be younger than 18 years at
cohort entry or to be pregnant during the study period.
However, in several patients, diagnoses indicating liver or
renal impairment were detected, which decreased when
narrowing the time window to 180 days prior cohort
entry and during rivaroxaban treatment. Given the high
potential of changes in liver and renal function over time,
which was reflected by the two time windows examined,
fewer patients may have met the criteria of impairment of
liver or renal function during the short treatment period.
Additionally, though GePaRD does not provide laborato-
ry data necessary for calculation of the impairment’s
severity none of those patients for whom a stage of
chronic renal failure could be deduced from the ICD
codes fulfilled the severity of renal impairment described
as contraindications and precautions.
Table 4 Patients receiving potentially interacting drugs prescribed in










CYP3A4 inhibitors 11 (2.5 %) 2 (0.5 %)
CYP3A4 inducers 3 (0.7 %) 2 (0.5 %)
P-gp inhibitors 6 (1.4 %) 3 (0.7 %)
Drugs affecting haemostasis 212 (48.2 %) 164 (37.3 %)
NSAIDs 203 (46.1 %) 159 (36.1 %)
Platelet aggregation inhibitors 7 (1.6 %) 1 (0.2 %)
Heparins and fondaparinux 15 (3.4 %) 5 (1.1 %)
Vitamin K antagonists 0 (0.0 %) 0 (0.0 %)
*Totals may not add up if patients received drugs from different
categories
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Though examining potentially interacting drugs beyond
those stated in the SPC, prescribing of medications with
possible pharmacokinetic interactions during rivaroxaban
treatment was rare and included none of the drugs not recom-
mended for concomitant use. On the contrary, nearly half of
the patients received NSAIDs which may interact via phar-
macodynamic mechanisms. However, these drugs constitute
plausible co-medications used to reduce post-operative pain
and inflammation [16]. NSAID prescriptions were slightly
lower compared to a Dutch study which reported 52 % of
patients receiving NSAIDs after HR or KR [17] and substan-
tially lower than has been reported by an analysis of
rivaroxaban clinical trials where over 70 % of patients with
HR or KR concomitantly used NSAIDs [18]. Since these
studies supposedly included also NSAIDs administered in
hospital [17, 18] these differences might be referred to a
higher use in the first days after surgery. Prescribing of
LMWH or fondaparinux during an estimated rivaroxaban
treatment may indicate a change of therapy for example
because of side effects. As VTE prophylaxis has been tradi-
tionally conducted with subcutaneous injections, insufficient
knowledge about the new oral anticoagulants might have
contributed to these findings as well. Since no prescribing of
VKA was found in temporal relationship with rivaroxaban
treatment there was no hint that rivaroxaban was used as
bridging therapy in patients treated with VKA before or after
the surgical intervention. As this study was not designed as a
safety analysis, we did not examine whether these concomi-
tantly prescribed drugs resulted in adverse effects.
Strengths of this study are the size of the underlying pop-
ulation and the lack of non-response due to the nature of
administrative data [19]. Determination of drug therapy based
on pharmacy dispensing data is considered the gold standard
as recall bias can be ruled out and information is precise in
time and dose [9]. By reconstructing and including inpatient
treatment, we were able to depict the complete
thromboprophylaxis following orthopaedic surgery for these
patients while a restriction to outpatient prescriptions would
have led to an underestimation of treatment time.
Limitations are mainly attributable to the nature of the
administrative data. GePaRD does not include medication
bought over the counter, thus an underestimation of e.g.
NSAIDs is likely. Another shortcoming of our study was that
it did not include a review of individual patient files which for
data protection reasons is not feasible in Germany. So, al-
though the respective inpatient procedures could be referred to
an exact date and effective VTE prophylaxis is reported to be
standard care in surgical wards in Germany [20], we had no
possibility to verify that in patients receiving outpatient pre-
scriptions of rivaroxaban thromboprophylaxis was actually
started in hospital on the day of surgery.
A further limitation was that the duration of rivaroxaban
treatment had to be estimated based on the prescribed package
sizes since GePaRD does not provide the intended length of
treatment. When rivaroxaban was introduced in Germany,
packages of 10 or 30 tablets were available; an additional
package size of 5 tablets was marketed later. As co-
payment is required per package, patients might have been
prescribed larger packages and told to stop earlier which in our
study would have led to an overestimation of treatment time.
Based on the recommended treatment durations and the pack-
age sizes available, it is likely that this scenario applied more
often to those patients receiving rivaroxaban following knee
replacement.
On the other hand, an underestimation of treatment dura-
tion could have resulted from observation periods being cen-
sored by either the end of the study or patients being hospi-
talized leading to inpatient rivaroxaban treatment. Overall,
15% of episodes were censored; however, this applied to only
6 % of the episodes found to be shorter than recommended.
As no direct linkage is possible between prescriptions and
corresponding indications, misclassification cannot be ruled
out; however, the examined hospital procedures provided
detailed information allowing for a distinction between
rivaroxaban use following labelled and non-labelled surgeries.
By adding information from diagnoses during the same hos-
pital stays, we were able to differentiate between elective and
fracture surgery as well. Given the high proportion of on-label
indications examined it seems unlikely that misclassification
is of great importance.
In conclusion, our study did not identify important off-label
use of rivaroxaban, apart from that of extended treatment
duration which might partly result from the estimation of
treatment duration based on the package size of the prescription.
Additionally, given the comparatively short recommended
treatment durations in both indications, our study might have
missed patients who were treated according to recommen-
dations in hospital and during a possible stay in a rehabilitation
clinic without receiving any outpatient rivaroxaban
prescriptions.
Based on several assumptions, our study also provides an
example of reconstructing inpatient drug use in a healthcare
database which does not contain prescription information in
hospital when treatment is continued in the outpatient setting.
This approach requires that (i) the indication of the drug of
interest and thus the start of in-hospital treatment can be
specifically linked to an operation or procedure code with an
exact date, (ii) a change of treatment between the in- and
outpatient setting is unlikely and (iii) especially for short-
time treatment only a small gap between hospital discharge
and the first outpatient prescription can be expected. This
approach might be useful for DUS dealing with the problem
of drug use starting in hospital. However, possible limitations
resulting from these assumptions should be considered care-
fully when interpreting the results especially when estimating
treatment durations.
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